Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAT-001
- Development stage
- Preclinical
- Lead developer
- New G Lab
- Modality
- Small Molecules
01
Overview
KAT-001 is a preclinical-stage small molecule anticancer therapeutic being developed by NewG Lab Pharma. The drug is designed to target the Warburg Effect, a metabolic hallmark of cancer characterized by aerobic glycolysis, where tumor cells metabolize glucose through glycolysis even in the presence of oxygen. By targeting this altered metabolic pathway, KAT-001 aims to disrupt the energy production and biosynthetic mechanisms that cancer cells rely on for rapid growth and survival. It is currently in preclinical development for the treatment of liver cancer, specifically hepatocellular carcinoma, with plans to transition into clinical trials.
Beyond the preview
Go deeper on KAT-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAT-001.